|
Match
|
Document |
Document Title |
|
|
6893813 |
Methods for treatment of HIV and other infections using a T cell or viral activator and anti-retroviral combination therapy
Disclosed is a method for treating infection with a pathogen. The method involves administration of: (1) a substance which induces active pathogen replication in a cell latently infected with HIV...
|
|
|
6893812 |
Three-dimensional ex vivo angiogenesis system
An in vitro tissue angiogenesis and vasculogenesis system is disclosed that allows the outgrowth of microvessels from a three-dimensional tissue fragment implanted in a matrix. The matrix may, for...
|
|
|
6890908 |
Modified ribozymes
The present invention refers to an RNA molecule with catalytic activity comprising at least one modified nucleoside, wherein the hydroxy group at the 2′-position of the ribose sugar is replaced...
|
|
|
6890753 |
Modified rapid expansion methods(“modified-REM”) for in vitro propagation of T lymphocytes
The present invention provides a modified rapid expansion method (termed “low-PBMC-REM” or “modified-REM”), for quickly generating large numbers of T lymphocytes, including cytolytic and...
|
|
|
6890542 |
Leishmania vaccine
The present invention relates to the use of a live mutant Leishmania in the preparation of a vaccine and to vaccine formulations for use in immunizing mammals, such as dogs and/or humans. The...
|
|
|
6884787 |
Antisense modulation of transforming growth factor-beta 3 expression
Antisense compounds, compositions and methods are provided for modulating the expression of transforming growth factor-beta 3. The compositions comprise antisense compounds, particularly antisense...
|
|
|
6884619 |
Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
The present invention relates to primary CNS tumors and provides useful compositions and methods for reducing tumor volume and increasing the length of survival in mammals with primary CNS tumors,...
|
|
|
6881575 |
Compositions and methods for inhibiting G2 cell cycle arrest and sensitizing cells to DNA damaging agents
The invention provides compositions and methods for inhibiting Chk1 and/or Chk2 kinases. Also provided are compositions and methods for inhibiting G2 cell arrest checkpoint, particularly in...
|
|
|
6881413 |
Humanized biomaterials, a process for their preparation and their applications
The invention relates to humanized biomaterial comprising a porous biocompatible composite material customized and implanted with monocyte derived cells preferably with macrophages.
|
|
|
6878546 |
Product and method for swelling a cell nucleus without DNA replication
The present invention concerns products and methods particularly useful for activating and analyzing non-dividing cell nuclei. The featured products include activating egg extracts, cytostatic...
|
|
|
6875749 |
Methods of facilitating vascular growth
A method of facilitating vascular growth in a subject in need of such treatment comprises inhibiting EMAP II activity in the subject by an amount effective to stimulate vascular growth in the...
|
|
|
6875430 |
Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
A method of reducing an immune response to a transplant in a recipient by treating said recipient with an amount of mesenchymal stem cells effective to reduce or inhibit host rejection of the...
|
|
|
6875747 |
Antisense to c-myc for treatment of polycystic kidney disease
A method of treating polycystic kidney disease by administering an oligonucleotide antisense to c-myc is described. The antisense oligonucleotide is preferably a morpholino oligonucleotide.
|
|
|
6869795 |
Antisense compositions and cancer-treatment methods
A composition antisense oligomer directed to an mRNA preferentially expressed together with methods for treating stem cells with such a composition to increase the number of lineage committed...
|
|
|
6867197 |
Method of targeting conjugate molecules to mitochondria
The present invention relates to genetic mutations in mitochondrial cytochrome c oxidase genes that segregate with Alzheimer's disease (AD). The invention provides methods for detecting such...
|
|
|
6867039 |
Antisense modulation of dual specific phosphatase 5 expression
Antisense compounds, compositions and methods are provided for modulating the expression of dual specific phosphatase 5. The compositions comprise antisense compounds, particularly antisense...
|
|
|
6867043 |
Peptides that deliver antisense oligonucleotides which downregulate protein expression in cells
The present invention provides a peptide that can complex with an oligonucleotide, e.g. an antisense oligonucleotide, and deliver it into a cell. The present invention also provides compositions...
|
|
|
6864224 |
Kinase inhibitors and methods of use in screening assays and modulation of cell proliferation and growth
The invention relates to the discovery of a novel amino acid sequence motif, herein termed the RKIP motif, and to the family of proteins defined by the presence of that motif. Proteins comprising...
|
|
|
6861233 |
Method of screening for triacyglycerol hydrolase inhibitors
The invention relates to methods of identifying therapeutic agents which inhibit triacyglycerol hydrolase (TGH) activity, defined as TGH inhibitors, which are useful in the treatment of conditions...
|
|
|
6861257 |
Methods for isolation of osteoclast precursor cells and inducing their differentiation into osteoclasts
This invention relates to: a method for differentiating osteoclast precursor cells (preosteoclasts) into osteoclasts, which comprises culturing the preosteoclasts in the absence of accessory cells;...
|
|
|
6858399 |
Test for oxidative stress using cell suspensions
This invention provides a method of measuring oxidative response of cells without recourse to preparation of cell culture. The process involves:
1) preparing suspensions of cells from a...
|
|
|
6858429 |
Universal light-switchable gene promoter system
An artificial promoter system that can be fused upstream of any desired gene enabling reversible induction or repression of the expression of the gene at will in any suitable host cell or organisms...
|
|
|
6855317 |
Immunological herpes simplex virus antigens and methods for use thereof
The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by...
|
|
|
6855546 |
Controlling availability or activity of proteins by use of protease inhibitors or receptor fragments
The invention relates to the field of proteins, more specifically to those proteins that are located on the surface of the cell. The invention, amongst others, provides an inhibitor or...
|
|
|
6855700 |
Antisense modulation of damage-specific DNA binding protein 1, p127 expression
Antisense compounds, compositions and methods are provided for modulating the expression of Damage-specific DNA binding protein 1, p127. The compositions comprise antisense compounds, particularly...
|
|
|
6852536 |
Antisense modulation of CD36L 1 expression
Antisense compounds, compositions and methods are provided for modulating the expression of CD36L1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted...
|
|
|
6852535 |
Polymerase III-based expression of therapeutic RNAS
A transcribed non-naturally occurring RNA molecule comprising a desired RNA molecule, wherein the 3′ region of the RNA is able to base-pair with at least 8 bases at the 5′ terminus of the same...
|
|
|
6843991 |
Use of the M3 protein of MHV68 to block binding of a chemokine to its receptor
A pharmaceutical composition comprises M3 protein as encoded by virus MHV 68, or a homologue of said M3 protein, for use in binding to a chemokine or a chemokine analogue in vivo, or to block...
|
|
|
6841386 |
Modulation of primary stem cell differentiation using an insulin-like growth factor binding protein
The present invention features methods of modulating primary stem cell differentiation in culture by altering the endogenous activity of an insulin-like growth factor.
|
|
|
6841539 |
Compositions and methods for topical delivery of oligonucleotides
The present invention relates to compositions and methods which enhance the delivery of oligonucleotides and other nucleosidic moieties via topical routes of administration. Preferred compositions...
|
|
|
6841385 |
Transcription factor E2F DNA-binding domain inhibitor peptides and their use
The present invention provides peptides which bind to the DNA binding domain of transcription factor E2F, and inhibit cell cycle progression. Peptides include FWLRFT (SEQ ID NO:1); WVRWHF (SEQ ID...
|
|
|
6841542 |
Transforming growth factor beta (TGF-β) blocking agent-treated stem cell composition and method
The invention relates to TGF-β blocking agent-treated HSC compositions and methods comprising the same. The TGF-β blocking agent-treated stem cells are viable for an extended time in culture...
|
|
|
6833247 |
Regulated prostate cancer genes
The present invention relates to all facets of novel polynucleotides, the polypeptides they encode, antibodies and specific binding partners thereto, and their applications to research, diagnosis,...
|
|
|
6831171 |
Nucleic acid catalysts with endonuclease activity
The present invention relates to novel Nucleic acid catalysts, methods of synthesis, and uses thereof.
|
|
|
6828148 |
Miniribozymes active at low magnesium ion concentrations
This invention is directed to a class of miniribozymes, capable of hybridizing with a target RNA to be cleaved and exhibiting very high cleavage rates at low Mg 2+ concentration. The miniribozymes...
|
|
|
6828149 |
Antisense modulation of PPP3R1 expression
Antisense compounds, compositions and methods are provided for modulating the expression of PPP3R1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted...
|
|
|
6828105 |
Antisense antiviral agent and method for treating ssRNA viral infection
The invention provides antisense antiviral compounds and methods of their use in inhibition of growth of viruses of the picornavirus, calicivirus, togavirus and flavivirus families, as in treatment...
|
|
|
6828147 |
Method of modifying cytotoxic cells and uses thereof
TALL-104 cells, and other cytotoxic T cell lines, may be modified to increase the cytotoxicity thereof, to enhance growth properties, and/or to provide a preferred phenotype, e.g., expression of...
|
|
|
6825337 |
Antisense modulation of PLML expression
Antisense compounds, compositions and methods are provided for modulating the expression of PLML. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to...
|
|
|
6824973 |
Method of promoting stem cell proliferation or survival by contacting a cell with a stem cell factor-like polypeptide
The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human stem cell growth factor-like protein....
|
|
|
6825174 |
Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
A pharmaceutical composition effective for preventing and alleviating bronchoconstriction, lung allergy(ies) and inflammation comprises a surfactant and an oligonucleotide anti-sense to an...
|
|
|
6824986 |
Methods for measuring in vivo cytokine production
The present invention involves techniques for evaluating in vivo cytokine production through the in vivo capture of secreting cytokines by labeled cytokine-binding reagents, followed by in vitro...
|
|
|
6821956 |
Therapeutic use of cis-element decoys in vivo
The invention provides for the use of oligodeoxynucleotide decoys for the prophylactic or therapeutic treatment of diseases associated with the binding of endogenous transcription factors to genes...
|
|
|
6821516 |
Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions
The invention relates to macrophages which have at least one of the following properties: their cytotoxic activity without IFN-γ is increased by about 20 to 30% with respect to standard...
|
|
|
6815203 |
Methods of making pancreatic islet cells
The invention features methods of promoting dedifferentiation of pancreatic cells, methods of obtaining pancreatic islet cells from the dedifferentiated pancreatic cells, and methods of treating a...
|
|
|
6808704 |
Method for generating immune-compatible cells and tissues using nuclear transfer techniques
This invention relates to methods for making immune compatible tissues and cells for the purpose of transplantation and tissue engineering, using the techniques of nuclear transfer and cloning....
|
|
|
6809194 |
Akt3 inhibitors
Inhibitors of human Akt3, including antisense oligonucleotides, methods, and compositions specific for human Akt3, are provided. Methods of using the compositions for modulating Akt3 expression and...
|
|
|
6809193 |
Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase (JNK protein) are...
|
|
|
6805869 |
Cellular vaccines and immunotherapeutics and methods for their preparation
The present invention provides a method for enhancing the immunogenicity of weakly immunogenic or non-immunogenic cells, resulting in a cellular vaccine that can stimulate T cell activation, which...
|
|
|
6806258 |
Antisense oligonucleotide modulation of raf gene expression
Oligonucleotides are provided which are targeted to nucleic acids encoding human raf and capable of inhibiting raf expression. The oligonucleotides may have chemical modifications at one or more...
|